Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Follow-Up Questions
Qui est le CEO de Prelude Therapeutics Inc ?
Dr. Krishna Vaddi est le Chief Executive Officer de Prelude Therapeutics Inc, il a rejoint l'entreprise depuis 2016.
Quelle est la performance du prix de l'action PRLD ?
Le prix actuel de PRLD est de $0.995, il a increased de 1.03% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Prelude Therapeutics Inc ?
Prelude Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Prelude Therapeutics Inc ?
La capitalisation boursière actuelle de Prelude Therapeutics Inc est de $56.3M
Est-ce que Prelude Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour Prelude Therapeutics Inc, y compris 3 achat fort, 5 achat, 1 maintien, 1 vente et 3 vente forte
